Abstract: The SWI/SNF chromatin-remodeling complexes play critical roles in transcriptional regulation and DNA repair, making them significant targets in oncology. BRM014 is a potent, orally active, allosteric dual inhibitor of the SWI/SNF ATPases BRM (SMARCA2) and BRG1 (SMARCA4). Initially developed to exploit the synthetic lethal relationship in BRG1-mutant cancers, BRM014 has demonstrated robust antiproliferative activity by downregulating BRM-dependent gene expression. Recent studies have expanded its therapeutic utility, revealing that BRM014 impairs homologous recombination (HR) by inhibiting DNA end resection, thereby sensitizing cancer cells to DNA double-strand break-inducing agents and PARP inhibitors. Furthermore, BRM014 treatment induces micronuclei formation and activates the cGAS/STING innate immune response. Despite dose-limiting tolerability challenges in vivo due to its dual-inhibition profile, BRM014 represents a valuable pharmacological tool and a promising lead for combination therapies in both SWI/SNF-dependent and homologous recombination-proficient cancers.
1. Introduction
Aberrant regulation of transcriptional programs through defects in chromatin-remodeling activity is a hallmark of many cancers. Mutations in the multisubunit SWI/SNF chromatin-remodeling complexes occur in approximately 20% of human malignancies [1]. BRG1 (SMARCA4) and BRM (SMARCA2) are the mutually exclusive catalytic ATPases of these complexes [1]. BRG1 is frequently mutated in non-small-cell lung cancer (NSCLC), melanoma, and other cancers [1]. Genetic screens have identified a synthetic lethal relationship between BRG1 and BRM, where BRG1-deficient cancer cells become exquisitely dependent on BRM ATPase activity for survival [1]. This dependency drove the discovery of BRM014 (identified as compound 14 during its medicinal chemistry optimization), a potent, orally active dual inhibitor of the BRM and BRG1 ATPases [1].
Beyond transcriptional regulation, SWI/SNF complexes are crucial for DNA double-strand break (DSB) repair [2]. Consequently, BRM014 has emerged not only as a targeted therapy for BRG1-mutant cancers but also as a potent agent to disrupt DNA repair mechanisms, thereby enhancing the efficacy of existing chemotherapies in various oncological contexts [2].
2. Pharmacological Activity
BRM014 exhibits significant pharmacological activity across various in vitro and in vivo cancer models. In vitro, it potently inhibits the proliferation of BRG1-mutant lung cancer cells (e.g., H1299) and cutaneous melanoma cells (SKMEL5), while sparing target-deficient cells (SBC5) [1]. In vivo, oral administration of BRM014 in a BRG1-mutant RERF-LC-AI human lung tumor xenograft model resulted in dose-dependent tumor growth inhibition (up to 55% at 20 mg/kg daily) and modulation of pharmacodynamic markers, such as the downregulation of KRT80 mRNA [1].
In addition to its monotherapy efficacy in SWI/SNF-addicted cancers, BRM014 displays profound synergistic activity with DNA-damaging agents. In U2OS osteosarcoma and MDA-MB-231 triple-negative breast cancer (TNBC) cells, BRM014 sensitizes cells to chemotherapeutics such as camptothecin, bleomycin, cisplatin, and etoposide [2]. Importantly, while BRG1 knockout cells are typically resistant to PARP inhibitors (PARPi), dual inhibition of BRG1 and BRM by BRM014 strongly sensitizes these cells to PARPi like olaparib and talazoparib, highlighting BRM's backup role in DNA repair when BRG1 is absent [2].
3. Molecular Mechanism of Action
The molecular mechanism of BRM014 is multifaceted, impacting both chromatin remodeling-dependent transcription and DNA repair pathways:
ATPase Inhibition: BRM014 functions as an allosteric inhibitor that binds in the vicinity of the ATP-binding site of the BRM/BRG1 ATPase domain [1]. By inhibiting ATP hydrolysis, it prevents the SWI/SNF complex from sliding and evicting nucleosomes, leading to the downregulation of BRM-dependent gene expression, such as KRT80 [1].
Impairment of Homologous Recombination (HR): BRM014 disrupts the repair of DNA DSBs by impairing the DNA end resection step of HR [2]. Treatment with BRM014 significantly reduces the accumulation of chromatin-bound Replication Protein A (RPA) and phosphorylated RPA (pRPA) at damage sites [2]. Consequently, the suppression of HR forces cells to utilize the more error-prone non-homologous end joining (NHEJ) pathway, leading to genomic instability and an accumulation of DSBs [2].
Activation of cGAS/STING Pathway: The genomic instability induced by BRM014, particularly when combined with PARPi, results in the formation of micronuclei [2]. These micronuclei can rupture and release DNA into the cytoplasm, which is detected by cGAS, triggering the STING innate immune response [2]. This activation leads to the phosphorylation of NFκB and the subsequent transcription of pro-inflammatory cytokines (e.g., IFNB1, CXCL10, CCL5) [2].
4. Structure-Activity Relationship (SAR)
The discovery of BRM014 originated from a high-throughput screen identifying a dipyridyl urea scaffold [1]. SAR optimization revealed several critical features for target engagement:
Urea Core: The urea moiety is absolutely essential for activity. X-ray crystallography demonstrated that the urea traps the catalytic glutamate (Glu852) in an "out" conformation via a bidentate hydrogen-bonding interaction with the urea N-H groups [1]. An additional hydrogen bond is formed with the Gln885 backbone [1].
Pyridine Substitutions: A 2-halo-4-substituted pyridine motif is required for inhibitory activity [1]. Replacing the chlorine atom with a fluorine atom (as seen in the transition to compound 14/BRM014) improved both biochemical potency and thermodynamic solubility [1].
Conformational Preference: Analysis of the scaffold indicated a strong preference for a flat, trans urea binding conformation. Modifications that favored a cis conformation via intramolecular hydrogen bonding or twisted the ring out-of-plane due to unfavorable electrostatic interactions were highly detrimental to potency [1].
5. Current Limitations
While BRM014 is highly potent, its clinical translation faces significant challenges. The primary limitation is dose-limiting toxicity in vivo. In xenograft models, attempts to drive sustained pharmacodynamic inhibition with higher doses (e.g., 30 mg/kg) resulted in significant body-weight loss and tolerability issues [1]. This toxicity is likely mechanism-based, stemming from the compound's lack of selectivity between BRM and BRG1 [1]. Because BRM and BRG1 share 92% sequence identity in their ATPase domains, BRM014 acts as a dual inhibitor [1]. Dual inactivation of BRM and BRG1 is known to be lethal in normal tissues, leading to a narrow therapeutic window [1].
6. Future Perspectives
The dual functionality of BRM014 opens novel therapeutic avenues. For cancers that do not inherently depend on SWI/SNF-mediated oncogene expression (like MYC), BRM014 can be repurposed as a potent sensitizer to DNA-damaging chemotherapy and PARP inhibitors [2]. Furthermore, the ability of BRM014 to activate the cGAS/STING pathway and induce a pro-inflammatory cytokine response suggests a strong rationale for combining SWI/SNF inhibitors with immune checkpoint blockade to turn immunologically "cold" tumors "hot" [2]. Future drug discovery efforts must focus on identifying highly selective BRM inhibitors to widen the therapeutic index and mitigate the toxicities associated with dual BRM/BRG1 inhibition [1].
